Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Evaluation of the use of therapeutic peptides for cancer treatment.

Marqus S, Pirogova E, Piva TJ.

J Biomed Sci. 2017 Mar 21;24(1):21. doi: 10.1186/s12929-017-0328-x. Review.

2.

Defining the endpoints: how to measure the efficacy of drugs that are active against central nervous system metastases.

Fabi A, Vidiri A.

Transl Lung Cancer Res. 2016 Dec;5(6):637-646. doi: 10.21037/tlcr.2016.11.02. Review.

3.

The prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes: a SEER based study.

Wang H, Zhang C, Zhang J, Kong L, Zhu H, Yu J.

Oncotarget. 2017 Apr 18;8(16):26368-26379. doi: 10.18632/oncotarget.14300.

4.

Pretreatment clinical prognostic factors for brain metastases from breast cancer treated with Gamma Knife radiosurgery.

Roehrig AT, Ferrel EA, Benincosa DA, MacKay AR, Ling BC, Carlson JD, Demakas JJ, Wagner A, Lamoreaux WT, Fairbanks RK, Call JA, Cooke BS, Peressini B, Lee CM.

Surg Neurol Int. 2016 Nov 14;7(Suppl 35):S830-S836. eCollection 2016.

5.

Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells.

Yu T, Cho BJ, Choi EJ, Park JM, Kim DH, Kim IA.

Oncotarget. 2016 Nov 29;7(48):79089-79100. doi: 10.18632/oncotarget.12597.

6.

Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment.

Koo T, Kim IA.

Radiat Oncol J. 2016 Mar;34(1):1-9. doi: 10.3857/roj.2016.34.1.1. Epub 2016 Mar 30. Review.

7.

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU.

J Clin Oncol. 2016 Mar 20;34(9):945-52. doi: 10.1200/JCO.2015.63.0343. Epub 2016 Feb 1.

8.

Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases.

Subbiah IM, Lei X, Weinberg JS, Sulman EP, Chavez-MacGregor M, Tripathy D, Gupta R, Varma A, Chouhan J, Guevarra RP, Valero V, Gilbert MR, Gonzalez-Angulo AM.

J Clin Oncol. 2015 Jul 10;33(20):2239-45. doi: 10.1200/JCO.2014.58.8517. Epub 2015 May 18.

9.

Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.

Shen Q, Sahin AA, Hess KR, Suki D, Aldape KD, Sawaya R, Ibrahim NK.

Oncologist. 2015 May;20(5):466-73. doi: 10.1634/theoncologist.2014-0107. Epub 2015 Mar 23.

10.

Analysis of prognostic factors and comparison of prognostic index scores in patients with brain metastases after whole-brain radiotherapy.

Luo J, Zhu H, Tang Y, Wang H, Zhou X, Lu X, Zhang S, Li Y.

Int J Clin Exp Med. 2014 Dec 15;7(12):5217-25. eCollection 2014.

11.

miR-509 suppresses brain metastasis of breast cancer cells by modulating RhoC and TNF-α.

Xing F, Sharma S, Liu Y, Mo YY, Wu K, Zhang YY, Pochampally R, Martinez LA, Lo HW, Watabe K.

Oncogene. 2015 Sep 10;34(37):4890-900. doi: 10.1038/onc.2014.412. Epub 2015 Feb 9.

12.

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.

Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, Miles D, Samant M, Welslau M, Diéras V.

Ann Oncol. 2015 Jan;26(1):113-9. doi: 10.1093/annonc/mdu486. Epub 2014 Oct 29.

13.

Rationale for the use of upfront whole brain irradiation in patients with brain metastases from breast cancer.

Tallet AV, Azria D, Le Rhun E, Barlesi F, Carpentier AF, Gonçalves A, Taillibert S, Dhermain F, Spano JP, Metellus P.

Int J Mol Sci. 2014 May 8;15(5):8138-52. doi: 10.3390/ijms15058138. Review.

14.
15.
16.

Gamma knife radiosurgery for brain metastases from breast cancer.

Jo KI, Im YH, Kong DS, Seol HJ, Nam DH, Lee JI.

J Korean Neurosurg Soc. 2013 Nov;54(5):399-404. doi: 10.3340/jkns.2013.54.5.399. Epub 2013 Nov 30.

17.

Breaking and entering into the CNS: clues from solid tumor and nonmalignant models with relevance to hematopoietic malignancies.

Basu SK, Remick SC, Monga M, Gibson LF.

Clin Exp Metastasis. 2014 Feb;31(2):257-67. doi: 10.1007/s10585-013-9623-4. Epub 2013 Dec 5. Review.

18.

Breast cancer brain metastases: new directions in systemic therapy.

Lin NU.

Ecancermedicalscience. 2013 Apr 18;7:307. doi: 10.3332/ecancer.2013.307. Print 2013.

19.

Preclinical evaluation of oncolytic δγ(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastases.

Cody JJ, Scaturro P, Cantor AB, Yancey Gillespie G, Parker JN, Markert JM.

Int J Breast Cancer. 2012;2012:628697. doi: 10.1155/2012/628697. Epub 2012 Dec 31.

20.

Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the Pre-Trastuzumab and Trastuzumab eras.

Karam I, Hamilton S, Nichol A, Woods R, Speers C, Kennecke H, Tyldesley S.

Radiat Oncol. 2013 Jan 9;8:12. doi: 10.1186/1748-717X-8-12.

Supplemental Content

Support Center